PMID- 16929116
OWN - NLM
STAT- MEDLINE
DCOM- 20061214
LR  - 20180306
IS  - 1340-6868 (Print)
IS  - 1340-6868 (Linking)
VI  - 13
IP  - 3
DP  - 2006
TI  - HER-2 (c-erbB-2) test update: present status and problems.
PG  - 236-248
LID - 10.2325/jbcs.13.236 [doi]
AB  - HER-2 tests are routinely used for the identification of patients with metastatic 
      breast cancer that is potentially responsive to trastuzumab (herceptin) therapy. 
      Recently, convincing data have been published with regard to the efficacy of 
      trastuzumab as a drug for neoadjuvant therapy or adjuvant therapy for operable 
      primary breast cancer that overexpresses HER-2. It is also noteworthy that a the 
      St. Gallen International Consensus Conference 2005, HER-2 protein overexpression 
      or HER-2 gene amplification has been included as an indicator for higher risk of 
      recurrence for both node-negative and node-positive breast cancers. To measure 
      the HER-2 level, the worldwide consensus appears to be that immunohistochemistry 
      (IHC) should be performed first and, if the results of IHC are uncertain, 
      fluorescence in situ hybridization (FISH) should be performed later, although 
      some investigators argue that FISH should be performed first. These tests should 
      be performed in strict adherence to existing instructions. Quality control is of 
      utmost importance when performing HER-2 tests, both internal and external, for 
      routine diagnosis and in clinical protocol studies.
FAU - Tsuda, Hitoshi
AU  - Tsuda H
AD  - Department of Pathology II, National Defense Medical College, Japan. 
      htsuda@ndmc.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Japan
TA  - Breast Cancer
JT  - Breast cancer (Tokyo, Japan)
JID - 100888201
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/diagnosis/genetics/*metabolism
MH  - Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Research Design
RF  - 54
EDAT- 2006/08/25 09:00
MHDA- 2006/12/15 09:00
CRDT- 2006/08/25 09:00
PHST- 2006/08/25 09:00 [pubmed]
PHST- 2006/12/15 09:00 [medline]
PHST- 2006/08/25 09:00 [entrez]
AID - 10.2325/jbcs.13.236 [pii]
AID - 10.2325/jbcs.13.236 [doi]
PST - ppublish
SO  - Breast Cancer. 2006;13(3):236-248. doi: 10.2325/jbcs.13.236.